SEC 13F Intelligence

Tybourne Capital Management (Hk) Ltd / TSHA

Tybourne Capital Management (Hk) Ltd’s Taysha Gene Therapies Inc Position

Does Tybourne Capital Management (Hk) Ltd own Taysha Gene Therapies Inc (TSHA)? Yes3.70M shares worth $12M (+39.11% of its 13F portfolio) as of Q3 2025, down from 4.09M shares the prior filed quarter.

Position Value
$12M
Q3 2025
Shares
3.70M
% of Portfolio
+39.11%
Quarters Held
21
currently held

Position History TSHA

Reported value by quarter
Q3 ’20: $11MQ3 ’20Q4 ’20: $13MQ1 ’21: $10MQ2 ’21: $11MQ2 ’21Q3 ’21: $9MQ4 ’21: $6MQ1 ’22: $3MQ1 ’22Q2 ’22: $2MQ3 ’22: $965,000Q4 ’22: $3MQ4 ’22Q1 ’23: $1MQ2 ’23: $991,500Q3 ’23: $5MQ3 ’23Q4 ’23: $7MQ1 ’24: $11MQ2 ’24: $8MQ2 ’24Q3 ’24: $7MQ4 ’24: $6MQ1 ’25: $5MQ1 ’25Q2 ’25: $9MQ3 ’25: $12Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 20253.70M$12M+39.11%
Q2 20254.09M$9M+27.39%
Q1 20253.70M$5M+21.83%
Q4 20243.70M$6M+1.61%
Q3 20243.70M$7M+2.08%
Q2 20243.70M$8M+1.69%
Q1 20243.70M$11M+1.82%
Q4 20233.70M$7M+0.98%
Q3 20231.50M$5M+0.66%
Q2 20231.50M$991,500+0.11%
Q1 20231.50M$1M+0.12%
Q4 20221.50M$3M+0.34%
Q3 2022500.0K$965,000+0.09%
Q2 2022500.0K$2M+0.13%
Q1 2022500.0K$3M+0.19%
Q4 2021500.0K$6M+0.17%
Q3 2021500.0K$9M+0.23%
Q2 2021500.0K$11M+0.22%
Q1 2021500.0K$10M+0.22%
Q4 2020500.0K$13M+0.28%
Q3 2020500.0K$11M+0.28%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Tybourne Capital Management (Hk) Ltd’s full portfolio or all institutional holders of TSHA.